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Background
A combination of isoniazid (INH), rifampicin, pyrazina-
mide and/or ethambutol (anti-tuberculosis drugs, ATDs)
is commonly used for the treatment of tuberculosis. A
significant clinical problem is that drug treatment is
associated with mild elevations of liver enzymes that
occasionally develop into severe liver injury. The culprit
drug(s) and mechanistic basis of the reaction has not
been defined. Thus, the aims of this study were to (1)
explore whether drug-responsive T-lymphocytes were
detectable in patients with ATD-related liver injury, (2)
identify the drug(s) that activate T-cells and (3) charac-
terize the nature of the T-cell response.
Methods
A lymphocyte transformation test (LTT) and IFN-ELISpot
assay using ATDs and isonictinic acid (INA)-human
serum albumin (HSA) were performed on PBMCs from
20 ATD-related liver injury patients. HSA was coupled
with INA using synthesized N-hydroxysuccinimide acti-
vated ester of INA. Subsequently, patients were selected to
attempt to generate INH, rifampicin, pyrazinamide and
ethambutol-specific T-cell clones by serial dilution. Any
drug-responsive clones were then characterized in terms
of function and mechanism of antigen presentation. Anti-
gen present cells (APC) were (1) omitted from the assay,
(2) fixed with glutaraldehyde, (3) pulsed with INH, (4)
treated with MHC blocking antibodies and (5) cultured
with INH in the presence of N–acetyl-l-lysine (NAL) or
other reactive metabolites-trapping agents.
Results
PBMCs from 5 patients proliferated weakly after in vitro
stimulation with INH and INH-specific PBMC responses
were detectable using an IFN-ELISpot. INH, but not
rifampicin, pyrazinamide or ethambutol, specific T-cell
clones were generated from blood of the patients. The
clones proliferated and secreted cytokines when stimulated
with INH alone. They responded to APC pulsed with INH
for 16h and the response was inhibited by APC fixation
and with an anti-HLA class II blocking antibody. However,
NAL or other reactive metabolites-trapping agents did not
inhibit INH-specific proliferation.
Conclusion
These studies identify INH-specific T-cells in the blood
of certain patients with ATD-related liver injury and
characterize the nature of the drug-specific T-cell
response. Further experiments are needed to define the
way in which the drug interacts with MHC molecules to
stimulate T-cells.
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